


## Recommended algorithm for monitoring & management with OADs in patients admitted to hospital during these times by Ministry of Health & Family Welfare, Government of India.



If no, consult endocrinologist/physician [to start on basal-bolus insulin regimen or IV insulin infusion, depending on BG levels\*

Capillary BG monitoring in both section 2A and 2B: BBF, ABF, BL, AL, BDN and AND



<sup>\*</sup> Consult Endocrinologist/physician at earliest

## Roche Diabetes

And



## Guidance on the use of oral glucose lowering agents (Oral-GLAs)

**And** 



Prescribe oral-GLAs



No Contraindications for Oral-GLAs



Mild Infection



Mild Hyperglycemia (Pre-meal < 180 mg/dl) (Post-meal < 250 mg/dl)

Relatively Safe

## **Caution**

Stop if disease severity increases. Do not initiate if patients is not on these drugs

DPP-4 inhibitors

**Metformin:** Risk of lactic acidosis if moderately to severely ill with hemodynamic instability or hypoxia

**SGLT-2 Inhibitors:** Increase risk of dehydration and euglycemic ketoacidosis

Vidagliptin/ Teneligliptin/ Sitagliptin/ Linagliptin **Sulfonylureas:** Risk of hypoglycemia if oral intake is poor or with concomitant use of insulin therapy

**Pioglitazone:** Risk of fluid retention and edema; contraindicated in cardiac or hepatic dysfunction

Abbreviations: ADN: After dinner; BBF: Before breakfast, ABF: After Breakfast; BDN: Before dinner, BL: Before lunch, AL: After Lunch; BG: Blood glucose; CBG: Capillary blood glucose;

Clinical guidance on diagnosis and management of diabetes in COVID-19 patient management facility (version 2.0). Available at https://www.mohfw.gov.in/pdf/ClinicalGuidanceonDiagnosisandManagementofDiabetesatCOVID19 PatientManagementfacility.pdf. Last accessed on 16th June 2021.

